Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review

被引：25
|
作者：
Blayney, Douglas W. [1 ,3 ]
Schwartzberg, Lee [2 ]
机构：
[1] Stanford Canc Inst, Stanford, CA 75216 USA
[2] Univ Nevada, Renown Inst Canc, Reno, NV USA
[3] 875 Blake Wilbur Dr,Room CC-2219,M-C 6576, Stanford, CA 94305 USA
来源：
CANCER TREATMENT REVIEWS | 2022年 / 109卷
关键词：
Chemotherapy -induced neutropenia; G-CSF; Trilaciclib; Plinablin; Efbemalenograstim alpha; Eflapegrastim; INDUCED FEBRILE NEUTROPENIA; COLONY-STIMULATING FACTOR; RELATIVE DOSE INTENSITY; PER-CYCLE PEGFILGRASTIM; US CLINICAL-PRACTICE; BREAST-CANCER; PRIMARY PROPHYLAXIS; PLINABULIN PLIN; BIOSIMILAR FILGRASTIM; RECEIVING CHOP;
D O I：
10.1016/j.ctrv.2022.102427
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：10
相关论文
共 50 条
  • [1] Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia
    Ratti, Margherita
    Tomasello, Gianluca
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2015, 8 (01) : 15 - 24
  • [2] Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients
    Matikas, Alexios
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (02) : 157 - 166
  • [3] Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia
    Rofail, Pierre
    Tadros, Mariam
    Ywakim, Riham
    Tadrous, Mina
    Krug, Allison
    Cosler, Leon E.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (06) : 699 - 709
  • [4] Prevention and Treatment of Chemotherapy-Induced Febrile Neutropenia in Adults
    Park, Hye Min
    Pom, Boramey
    Farina, Kyle A.
    Rattu, Mohammad A.
    US PHARMACIST, 2023, 48 (04)
  • [5] RGB-02 (biosimilar pegfilgrastim) in the treatment of chemotherapy-induced neutropenia
    Santha, Dora
    Illes, Andras
    Aradi, Ildiko
    Horvat-Karajz, Karoly
    Kahan, Zsuzsanna
    FUTURE ONCOLOGY, 2019, 15 (18) : 2083 - 2092
  • [6] Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia
    Saloustros, Emmanouil
    Tryfonidis, Kostas
    Georgoulias, Vassilis
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (06) : 851 - 863
  • [7] A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia
    Lyman, Gary H.
    CURRENT OPINION IN HEMATOLOGY, 2011, 18 (01) : 1 - 10
  • [8] Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
    Gebremariam, Girma Tekle
    Fentie, Atalay Mulu
    Beyene, Kebede
    Sander, Beate
    Gebretekle, Gebremedhin Beedemariam
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [9] Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings
    Weycker, Derek
    Barron, Richard
    Kartashov, Alex
    Legg, Jason
    Lyman, Gary H.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2014, 20 (03) : 190 - 198
  • [10] Prevention of Chemotherapy-Induced Neutropenia with Pegfilgrastim: Pharmacokinetics and Patient Outcomes
    Yang, Bing-Bing
    Savin, Michael A.
    Green, Michael
    CHEMOTHERAPY, 2012, 58 (05) : 387 - 398
12345